Peptide Bio IndexEvidence first. Hype last.
⌕

Retatrutide Trial Discontinuations and Adverse-Event Patterns

Written by

in

Peptide Research Overviews
PBIPeptide Bio Index Editorial DeskSource-labeled research summary
Source-limited9 min readUpdated Sep 7, 2026
Jump to a section
  1. Trial evidence base and compound profile
  2. Reported discontinuations due to adverse events (trial-level)
  3. Adverse‑event patterns and timing reported
  4. Dose, starting‑dose strategy, and AE mitigation
  5. Phase 3 program context and upcoming data
  6. Interpretation caveats and evidence gaps
  7. Reported study-design details from cited sources
  8. Limitations and research gaps
  9. Documentation checklist
  10. Related research supplies
  11. More Retatrutide research
  12. Sources and references

Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.

This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.

Source-limited research note: The reviewed sources were incomplete, ambiguous, or insufficient for a normal article. This page labels missing details rather than guessing.

This deep dive summarizes reported trial discontinuation rates and adverse-event (AE) patterns for retatrutide across available phase 2 and phase 3 clinical reports and pooled analyses, focusing on AE types, timing, dose-related trends, and reported AE-related withdrawals in the reviewed literature (peer-reviewed trials, a systematic review/meta-analysis, and a phase 3 report).

Trial evidence base and compound profile

Retatrutide (LY3437943) is a single triple-hormone–receptor agonist (GIP, GLP‑1, and glucagon) that has been evaluated in randomized phase 2 trials and a phase 3 trial program; peer-reviewed phase 2 results and a phase 3 randomized trial in adults with type 2 diabetes are included among the reviewed records, and a multi-trial phase 3 registrational program (TRIUMPH) has been described in protocol form. (Sources summarized below.) [S7] [S3] [S2]

Reported discontinuations due to adverse events (trial-level)

Reported AE‑related discontinuation rates across reviewed trials were low in absolute terms but variable by report: the TRANSCEND‑T2D‑1 phase 3 trial reported study intervention discontinuations due to adverse events of 2–5% among retatrutide treatment arms versus 0% with placebo; phase 2 reports and pooled analyses described adverse-event withdrawals without signals of markedly elevated withdrawal risk versus comparators in head‑to‑head or pooled analyses, and systematic review/meta-analysis authors noted increased non‑severe gastrointestinal and hypersensitivity events but did not report a wholesale increase in AE withdrawals across the included trials. [S3] [S4] [S7] [S5] [S6]

Adverse‑event patterns and timing reported

Across the phase 2 and phase 3 reports the most frequent AEs were gastrointestinal (nausea, vomiting, and related events), typically described as dose‑related and generally mild to moderate in severity and tending to subside over time; phase 2 data also documented dose‑dependent increases in heart rate that peaked at 24 weeks and declined thereafter. Systematic and network meta-analyses of available randomized data reported increased non‑severe gastrointestinal and hypersensitivity events with retatrutide but did not identify consistent increases in serious adverse events or hypoglycaemia across included trials. [S7] [S3] [S4] [S5] [S6]

Dose, starting‑dose strategy, and AE mitigation

Phase 2 trial reports included multiple fixed target doses and staggered/step starting-dose approaches; investigators reported that gastrointestinal adverse events were dose-related and that use of a lower starting dose (eg, 2 mg initial dosing for some cohorts) partially mitigated these events compared with higher starting-dose schedules in the same trial. [S7] [S4]

Phase 3 program context and upcoming data

A multi‑trial phase 3 registrational program (TRIUMPH) has been designed to evaluate weekly subcutaneous retatrutide versus placebo across weight‑management and complication‑specific studies, enrolling over 5800 participants across four randomized trials; TRANSCEND‑T2D‑1, a completed phase 3 trial in adults with inadequately controlled type 2 diabetes, reported efficacy and an AE profile described as consistent with GLP‑1 activity in its peer‑reviewed report. [S2] [S3]

Interpretation caveats and evidence gaps

Available randomized evidence includes a limited number of published trials and pooled analyses, with varying durations and populations; systematic reviewers have emphasized that phase 3 RCTs will be important to clarify long‑term safety, AE‑related withdrawal patterns, and subgroup differences. The TRANSCEND‑T2D‑1 report and phase 2 trials document short‑to‑medium term AE patterns, but longer follow‑up and broader population data remain limited in the reviewed sources. [S5] [S6] [S3]

Reported study-design details from cited sources

The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.

Source Study Type Model / Subject Amount Reported Route Reported Frequency Duration Notes
[S7] Phase II randomized controlled trial Adults with obesity (BMI ≥30, or BMI 27– 1 mg; 4 mg (initial dose 2 mg or initial dose 4 mg); 8 mg (initial dose 2 mg or initial dose 4 mg); 12 mg (initial dose 2 mg) subcutaneous injection once weekly 48 weeks Randomized allocation to multiple fixed target doses and initial-dose variations; gastrointestinal AEs reported as dose-related and partially mitigated with lower starting dose; dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter. Total enrolled: 338 adults. Primary endpoint at 24 weeks.
[S3] Phase III randomized, double‑blind, placebo‑controlled trial Adults with type 2 diabetes inadequately controlled with diet and exercise (HbA1c 7.0–9.5%, BMI ≥23 kg/m2) 4 mg, 9 mg, 12 mg subcutaneous injection once weekly 40 weeks Participants randomized 1:1:1:1 to retatrutide 4 mg, 9 mg, 12 mg, or placebo. Most frequent AEs were generally mild to moderate gastrointestinal events that subsided over time; study intervention discontinuations due to adverse events were reported as 2–5% with retatrutide and 0% with placebo; no severe hypoglycaemia reported; two deaths occurred in the retatrutide 4 mg group and were reported as unrelated to study drug.
[S4] Phase II randomized, double‑blind, parallel‑group, placebo‑controlled trial (body composition substudy) Adults with type 2 diabetes (HbA1c 7.0–10.5%, BMI 25–50 kg/m2) enrolled in a body‑composition substudy retatrutide 0.5 mg, 4 mg (pooled initial-dose groups), 8 mg (pooled initial-dose groups), 12 mg; dulaglutide 1.5 mg; placebo subcutaneous injection once weekly 36 weeks (DXA endpoint at week 36) Multiple retatrutide dose cohorts (including different initial‑dose schedules) and active comparator dulaglutide 1.5 mg were included; gastrointestinal events were the most frequently reported AEs; serious adverse events occurred across treatment and placebo groups without a clear pattern of excess in retatrutide arms in this substudy population.
[S5] Systematic review and meta-analysis of randomized controlled trials Patients with overweight, obesity and/or type 2 diabetes enrolled across included RCTs various doses across included trials; 510 patients received retatrutide once‑weekly subcutaneous (as stated for included trials) once weekly not reported in the reviewed source Meta-analysis included three trials (640 patients total, 510 treated with retatrutide) and reported significant weight and metabolic improvements with retatrutide versus placebo and increases in non‑severe gastrointestinal and hypersensitivity adverse events; durations and exact dosing schedules varied across included trials and were not fully detailed in the reviewed excerpt.
[S2] Phase III registrational clinical trial program (protocol/basket trial design) Adults with obesity and selected complications (OSA, knee OA) across registry program cohorts weekly subcutaneous retatrutide (doses not detailed in the reviewed excerpt) subcutaneous injection weekly not reported in the reviewed source TRIUMPH program described as four Phase 3 randomized, double‑blind studies assessing weekly subcutaneous retatrutide versus placebo alongside lifestyle counselling; program planned to enroll over 5800 participants across weight‑management and complication‑specific trials.

Limitations and research gaps

  • This deep dive is limited to the provided reviewed source excerpts; full-text articles, supplementary appendices, and complete trial protocols were not available for interrogation here.
  • Cross‑trial comparisons are constrained by heterogeneous populations, dose-regimens, starting‑dose strategies, study durations, and AE reporting conventions in the reviewed excerpts.
  • Counts and rates reported here reflect what was explicitly stated in the reviewed excerpts; additional details (eg, exact reasons for each discontinuation, timing of individual AE resolution, or adjudication procedures for serious AEs) were not available in the provided material.

Documentation checklist

  • Confirm definition and denominator for 'discontinuation due to adverse event' used in each trial report before cross-trial comparison.
  • Report AE timing (onset, peak, resolution) separately for each trial rather than pooling where timepoints differ.
  • Verify starting-dose and up-titration schedules from full trial protocols when citing mitigation effects of lower starting doses.
  • Distinguish participant populations (eg, obesity vs T2D) when summarizing AE incidence or discontinuation rates.
  • For registry or sponsor data, cross-check with peer-reviewed reports for discrepancies in AE counts or withdrawal reasons.
  • Clinical trial adverse event log template (electronic case report form)
  • Clinical trial registry submission template (protocol and safety appendix)
  • Pharmacy cold‑storage inventory and temperature log
  • Laboratory sample labeling and tracking stickers

Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.

Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.

Batch and inventory labeling

Phomemo M110 Label and Barcode Printer

A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.

View on Amazon (paid link)

Label-printer refill

Phomemo M110 White Replacement Labels

White 1.57 × 0.78 inch replacement labels for compatible Phomemo printers. Confirm printer and label-size compatibility before ordering.

View on Amazon (paid link)

Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.

Research Supply Note: SourcePoint Research currently lists SPR-3RT for research-use-only sourcing. Review current availability and the exact batch documentation at SourcePointResearch.com. This article does not independently certify a SourcePoint batch. Peptide Bio Index is affiliated with SourcePoint Research.

More Retatrutide research

Sources and references

  1. [S1] Drucker DJ. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.. Diabetes care. 2024. PMID: 38843460. DOI: 10.2337/dci24-0003
  2. [S2] Giblin K, Kaplan LM, Somers VK, Le Roux CW, Hunter DJ, Wu Q. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.. Diabetes, obesity & metabolism. 2026. PMID: 41090431. DOI: 10.1111/dom.70209
  3. [S3] Bajaj HS, Welch M, Shah P, Luna E, Jaouimaa FZ, Liu B. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.. Lancet (London, England). 2026. PMID: 42250575. DOI: 10.1016/S0140-6736(26)00967-0
  4. [S4] Coskun T, Wu Q, Schloot NC, Haupt A, Milicevic Z, Khouli C. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.. The lancet. Diabetes & endocrinology. 2025. PMID: 40609566. DOI: 10.1016/S2213-8587(25)00092-0
  5. [S5] Pasqualotto E, Ferreira ROM, Chavez MP, Hohl A, Ronsoni MF, Pasqualotto T. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials.. Metabolism open. 2024. PMID: 39318607. DOI: 10.1016/j.metop.2024.100321
  6. [S6] Xie Z, Zheng G, Liang Z, Li M, Deng W, Cao W. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.. Metabolism: clinical and experimental. 2024. PMID: 39305981. DOI: 10.1016/j.metabol.2024.156038
  7. [S7] Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial.. The New England journal of medicine. 2023. PMID: 37366315. DOI: 10.1056/NEJMoa2301972
  8. [S8] Wang Y, Zhou Y, Wang Z, Ni Y, Prud'homme GJ, Wang Q. Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.. The Journal of clinical endocrinology and metabolism. 2025. PMID: 40489581. DOI: 10.1210/clinem/dgaf336

Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.

More posts